TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/507,343			
Filing Date	March 11, 2002			
First Named Inventor	Hideo Ema			
Art Unit	1636.			
Examiner Name	Daniel Sullivan			
Attorney Docket No.	790086.405USPC			

ENCLOSURES (abook all that applied									
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement; Form PTO-1449 Cited References Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Response to Missing Parts/Incomplete Application			Drawing(s) Request for Correcte Receipt Licensing-related Par Petition Petition to Convert to Provisional Application Power of Attorney, Revocation, Change Correspondence Add Declaration Statement under 37 (3.73(b) Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table	d Filing pers a on of ress		After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Other Enclosure(s) (please identify below):			
	CICALATIU	25.05	E ADDI ICANT ATTO	DNEV	00.4	OPNT			
Firm Name			tual Property Law Group PLLC			Customer Number 00500			
Signature	100h	لما	/Cen-	<u>-</u>	•				
Printed Name	Stephen Rosehman, Ph.D.								
Date	January 31,	2005	005		0.	43,058			
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Signature									
Typed or printed n	ame Jas	on An	iover		Date	: January 31, 2005			
This collection of information is	and the district of the same o	1				thic which is to file (and by the USPTO to			

This collection of information is required by 37 CFR 1.5. The increasion is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22513-1450.

Date 31, 2005

Jason Añoyer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Hideo Ema et al.

Int'l Application No.:

PCT/JP02/02265

U.S. Application No.:

10/507,343

Int'l Filing Date

March 11, 2002

Title

PROTEIN SUSTAINING UNDIFFERENTIATED STEM CELLS

Docket No.

790086.405USPC

Date

: January 31, 2005

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Copies of the cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

·**A**. ,

Applicants note that reference AG (Ema et al.) is written in Japanese. Unfortunately, an English language abstract is not available.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Stephen J. Roseman, Ph.D

Registration No. 43,058

Enclosures:

Postcard Form PTO-1449 Cited References (9)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

556375

Date: 01/31/05

FORM PTO-1449 (REV.7-80)				ATTY. DOCKET NO.		APPLICATION NO.					
(REV.7-80) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			790086.405USPC 10/507,343								
			APPLICANTS Lideo Employed								
			Hideo Ema et al. FILING DATE GROUP ART UNIT								
			March 11, 2002		GROO	IF ART UNIT					
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		CLASS S		SUBCLASS	FILING DATE IF APPROPRIATE			
	AA	- 20 (2									
FOREIGN PATENT DOCUMENTS											
		DOCUMENT	DATE	<u> </u>	COUNTRY				TRANSLATION		
		NUMBER	DATE		COUNTRY				YES	NO	
	AB	WO 00/05374	02/03/00	WIPO							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)											
-	AC		Brandon, C., et al., "WNT Signaling Modulates the Diversification of Hematopoietic Cells," <i>Blood 96</i> (13):4132-4141, December 15, 2000.						Cells,"		
	AD	i	Deasy, B., et al., "Mechanisms of Muscle Stem Cell Expansion with Cytokines," <i>Stem Cells</i> 20:50-60, 2002.								
				1 4	(D : 1 1 1 1 1 1						
	AE		Drouet, M. et al., "Cell Cycle Activation of Peripheral Blood Stream and Progenitor Cells Expanded Ex Vivo with SCF, FLT-3 Ligand, TPO, and IL-3 Results in Accelerated							ells	
		Expanded Exp									
		Granulocyte	Granulocyte Recovery in a Baboon Model of Autologous Transplantation but G ₀ /G ₁ and								
		S/G ₂ /M Graf	S/G ₂ /M Graft cell Content Does Not Correlate with Tranplantability," Stem Cells 19:436-								
		442, 2001.									
	AF	Drouet, M. e	uet, M. et al., "The Reduction of In Vitro Radiation-Induced Fas-Related Apoptosis in								
	CD34 ⁺ Progeniro Cells by SCF, FLT-3 Ligand, TPO, and IL-3 in Combination Resulted in										
					entiation," Stem Cells 1					<i>-</i>	
									" libbo		
	AG	I	Ema, H., et al., "Purification of Hematopoietic Cells and Their Clonal Analysis," <i>Jikken Igaku 19</i> (15):1977-1981, 2001.								
											
	AH		Hsieh, J-C., et al., "A New Secreted Protein that Binds to Wnt Proteins and Inhibits their								
			Activities," <i>Nature 398</i> :431-436, April 1999. Lako, M., et al., "Characterisation of <i>Wnt</i> Gene Expression During the Differentiation of								
	AI				-	_	_			10	
					ro: Role of Wnt3 in En		g Ha	aematopio	etic		
		Differentiation	on," <i>Mechan</i>	isms of De	velopment 103:49-59, 2	001.					
	AJ	Van Den Bei	g, D., et al.,	"Role Of N	Members of the Wnt Ger	ne Fam	nily i	in Human			
		Hematopoies	sis," Blood 9	2(9):3189-3	3202, November 1, 199	8					
EXAMINE	R				DATE CONSIDERED						
* EXAMINE	R: Ir	nitial if reference consider	red whether or not	criteria is in cor	nformance with MPEP 609. Draw	line throu	igh cit	ation if not in			
	11	ii ioioionee constuc	ies, miletici di lidi	CHICHA IS III COI	normance with MIFEF 007. DIAW	mic unou	ıgıı Cil	ation ii 110t iii			

conformance and not considered. Include copy of this form with next communication to applicant(s).